RetinalGenix Technologies Inc.
RetinalGeniX Technologies Inc., an ophthalmic research and development company, focuses on developing technologies to screen, monitor, diagnose, and treat ophthalmic, optical, and sight-threatening disorders. The company offers the Retinal Imaging Screening Device, a portable retinal imaging system providing a wide field of view without requiring pupil dilation; and RetinalCam, an in-home/remote location patient-activated monitoring and imaging device offering real-time communication and alerting system for physicians. It also develops RTG-2023 for the treatment of dry age-related macular degeneration; and RTG-2024 for the treatment of Alzheimer's syndrome dementia. The company was incorporated in 2017 and is based in Apollo Beach, Florida. RetinalGenix Technologies Inc. is a subsidiary of Sanovas Ophthalmology, LLC.
Moat, DCF and rating computed by our valuation engine (ported from the original Python model).